Market Overview

UPDATE: Credit Suisse Upgrades Baxter International Following Delay in U.S. Eloctate Approval

Share:
Related BAX
Earnings Scheduled For January 29, 2015
Baxter Receives FDA Approval for PHOXILLUM Solution for Electrolyte Management During Continuous Renal Replacement Therapy
The DGI 'Factual 48' Versus 'The Favored 44' (Seeking Alpha)

In a report published Monday, Credit Suisse analyst Bruce Nudell upgraded the rating on Baxter International (NYSE: BAX) from Neutral to Outperform, and raised the price target from $73.00 to $80.00.

In the report, Credit Suisse noted, “We're upgrading BAX to OP from Neutral given the 3-month delay in BIIB's US Eloctate approval, BAX's recent enrollment of its own long-acting rFVIII trial (which shortens the time to counter-marketing), review of data from BAX's transgenic mouse model (which allowed BAX to assess inhibitor risk associated with BAX 855) & given the potential for value creation should BAX split its Medical Products & Bioscience segments. We're increasing our 2014 sales/EPS estimates to $16.81B/$5.09 from $16.76B/$5.04 on the Eloctate delay (out-year estimates unchanged). We're also raising our TP to $80 from $73 on a slightly lower assumed WACC.”

Baxter International closed on Friday at $68.66.

Latest Ratings for BAX

DateFirmActionFromTo
Oct 2014BarclaysMaintainsOverweight
Oct 2014Credit SuisseMaintainsOutperform
Oct 2014Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Bruce Nudell Credit SuisseAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional